KLRS 8-K: SEC filing

Kalaris Therapeutics, Inc.

Filed with the SEC on Nov 10, 2026 · accession 0001193125-26-454454

KLRS filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Kalaris Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantKalaris Therapeutics, Inc.

Chief executive officerAndrew Oxtoby

✦ Ask GOAX AI about this filing — what it means for KLRS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for KLRS?

Click here

Frequently asked questions

What did KLRS file with the SEC on Nov 10, 2026?

KLRS filed a 8-K (SEC filing). Kalaris Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other KLRS SEC filings

Get alerts when KLRS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

KLRS overview KLRS analysis KLRS news Latest SEC filings